The Levy CIMAR’s Laboratory for Combinatorial Drug Regimen Design (LCDRD) for resistant and emerging pathogens is dedicated to advancing collaborative biomedical innovation in the fight against antimicrobial resistance (AMR).

Constructed with the support of an NIH C06 grant, the LCDRD is located on the 8th floor of the Tufts Biomedical Research and Public Health Building on the Health Sciences Campus in Boston. The 2,500-square-foot BSL2+ facility is purpose-built to accelerate research on multidrug-resistant and emerging pathogens and includes specialized spaces for tissue culture, pathogen handling, and a clinical isolate biobank.

Designed with collaboration at its core, the LCDRD brings together scientists, clinicians, and engineers from Tufts University, Tufts Medicine, and external partners to develop innovative therapeutic strategies.
Collaborators and clients from external institutions (both academic and industry) are welcome to contact the LCDRD for more information via the form below.

The LCDRD houses the DiaMOND platform (Diagonal Measurement of N-Way Drug Interactions), a high-throughput technology developed at Tufts for identifying synergistic drug combinations. Working with academic and industry collaborators, DiaMOND is being applied to pathogens on the CDC’s urgent threat list.

1. Grant funded collaborations with internal or external partners
2. Industry-sponsored projects resulting in shared data
3. Fee-for-service contracts

For fee-for-service contracts the IP typically resides with the partner institution. For grant-funded studies, standard IP-sharing policies between collaborating institutions would apply.

This multi-tiered access model ensures broad availability of LCDRD’s infrastructure, supports collaborative innovation, and enables rapid translation of research into therapeutic development.